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Summs~ 
The role of nitric oxide in the immune response to allogeneic tissue was explored in an in vivo 
cardiac transplant model in the rat. Nitric oxide production during organ rejection was demonstrated 
by elevations in systemic serum nitrite/nitrate levels and by electron paramagnetic resonance 
spectroscopy. Messenger RNA for the inducible nitric oxide synthase enzyme was detected in 
the rejecting aUografted heart, but not in the nonrejecting isografted heart. The enzyme was 
demonstrated to be biologically active by the in vitro conversion of t-arginine to t-dtrulline 
and was immunohistochemically  localized to the infiltrating inflammatory cells. Treatment with 
aminoguanidine, a preferential inhibitor of the inducible nitric oxide synthase isoform, prevented 
the increased nitric oxide production in the transplanted organ and significantly attenuated the 
pathogenesis of acute rejection. Aminoguanidine treatment prolonged graft survival, improved 
graft contractile function, and significantly reduced the histologic grade of rejection. These results 
suggest an important role for nitric oxide in mediating the immune response to allogeneic tissue. 
Inhibition of inducible nitric oxide synthase may provide a novel therapeutic modality in the 
management of acute transplant rejection and of other immune-mediated processes. 
cute rejection is mediated by humoral and cellular im- 
mune mechanisms, and is characterized  by an intense 
inflammatory cell infiltrate and progressive destruction of the 
grafted organ. Despite many recent advances in the under- 
standing of the immune system, the regulatory and effector 
mechanisms underlying the rejection process remain incom- 
pletely understood. Recent reports have demonstrated produc- 
tion of the free radical  nitric oxide (NO) 1 during organ 
transplant rejection (1, 2). NO is synthesized from the amino 
acid t-arginine by a family of enzymes, the nitric oxide syn- 
1 Abbreviations used in this paper: EPR, electron paramagnetic resonance; 
iNOS, inducible nitric oxide synthase; NO, nitric oxide; NOS, nitric oxide 
synthase; POD, postoperative day; RT-PCR, reverse transcriptase  PCR. 
Portions of this work were presented at the 30th Annual Meeting of the 
Society of Thoracic Surgeons, New Orleans,  LA 31 January-2 February 
1994. 
thases  (NOS),  and is involved in diverse physiologic and 
pathophysiologic  processes, including host immune defense, 
vasoregulation, neurotransmission, and diabetes  (3, 4). 
In addition to its role as a cellular messenger at low con- 
centrations,  NO  is thought to be involved in pathologic 
processes because of its cytotoxicity at high concentrations. 
The inducible form of NOS (iNOS) produces large amounts 
of NO, can be expressed in diverse cell types, and in part 
mediates the cytostatic and cytotoxic effector function of ac- 
tivated macrophages (5,  6).  Aminognanidine is a selective 
iNOS inhibitor (7) that recently has been demonstrated to 
attenuate the pathophysiologic sequelae of NO production 
in diabetes (8, 9), uveitis (10), and in experimental autoim- 
mune encephalomyelitis (11). Despite the detection of NO 
during the rejection process and the demonstration of the 
in vitro immunoregulatory properties of NO  (12-15),  the 
role of NO in the in vivo immune response  to aUogeneic 
tissue is unclear. This report demonstrates that NO is pro- 
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Volume  181  January 1995  63-70 duced during organ transplant rejection by the induction of 
iNOS in the inflammatory cells infiltrating the rejecting organ, 
and that inhibition ofiNOS with aminoguanidine significantly 
ameliorated  the pathogenesis  of acute rejection. 
Materials and Methods 
Heterotopic Rat Cardiac Transplant  Model.  Male 175-200 g Lewis 
(RT-11 major histocompatibility antigen haplotype) and ACI (KT- 
1  ~) rats were purchased  from Harlan-Sprague-Dawley (Indianapo- 
lis, IN). The animals received standard rat chow and water ad libitum 
and were housed and cared for in accordance with guidelines  set 
forth by the Washington University Committee for the Humane 
Care of Laboratory Animals and the National Institutes of Health 
regarding laboratory animal welfare. Allogeneic (Lewis donor to 
ACI  recipient)  and  syngeneic (ACI  to ACI)  heterotopic intra- 
abdominal cardiac transplantation was performed essentially as de- 
scribed (16). The grafted hearts were monitored by daily palpation 
and complete rejection was defined as the cessation of palpable con- 
tractile activity. 
Spectrofluorometric Determination of Serum Nitrite~Nitrate.  Sys- 
temic serum nitrite/nitrate levels were measured in blood samples 
taken from the thoracic inferior vena cava at the time of animal 
sacrifice. Red blood cells were removed by centrifugation and the 
resulting serum filtered through an Ultrafree-MC microcentrifuge 
filter (MiUipore Corp.; Bedford, MA) to remove the hemoglobin 
resulting from cell lysis. After conversion of nitrate to nitrite with 
nitrate reductase (Sigma Chemical Co., St. Louis, MO), total ni- 
trite was measured by reacting with 2,3-diaminonaphthalene (Al- 
drich Chemical Co., Milwaukee,  WI) under acidic conditions to 
form 1-(H)-naphthotriazole,  a fluorescent product, as described (17). 
The formation of 1-(/-/)-naphthotriazole was quantitated using a 
fluorescent plate reader (Pan&x; IDEXX Laboratories,  Inc., West- 
brook, ME) with excitation at 365 nm and emission read at 450 nm. 
Reverse Transcriptase (RT) PCR.  Transplanted  hearts were har- 
vested by rapid excision and flash frozen in liquid nitrogen. Total 
RNA was extracted using guanidinium thiocyanate as described 
(18). First strand cDNA was prepared from 1 #g of RNA using 
Superscript TM II RNase H- Reverse Transcriptase  (GIBCO-BRL, 
Gaithersburg, MD) under the conditions suggested by the sup- 
plier. Using a Roche Molecular Systems kit (Branchburg,  NJ) with 
1.5 mM MgC12, PCR was  performed with primers specific for 
iNOS (TAGAAACAACAGGAACCTACCA  and ACAGGGGTG- 
ATGCTCCCGGACA),  yielding  a  907-bp  product;  and  for 
glyceraldehyde-3-phosphate  dehydrogenase ([G3PDH]; GACTC- 
GAATTCTACCCACGGCAAGTTCAATGG and GACTCGAAT- 
TCAGGGGCGGAGATGATGACCC) to yield a 224-bp product. 
Cycle times were 1 min at 95~  1 rain at 60~  and 1 min at 
72~  for 30 cycles. 10% of the iNOS reaction was combined with 
5% of the G3PDH reaction and analyzed for the presence or ab- 
sence of the iNOS species by electrophoresis on a 1% agarose gel. 
iNOS Activity.  t-citruUine production was determined in al- 
lograft, isograft, and normal hearts as described  (19; n  =  3 for 
each group; all reagents from Sigma Chemical Co. unless other- 
wise indicated). The hearts were minced and homogenized with 
a Polytron homogenizer (Brinkmann Instruments, Inc., Westbury, 
NY) in 1.5 ml of deionized water containing 1 mM dithiothreitol 
(DTT), 1 #M tetrahydrobiopterin, 2 #M flavin adenine dinucleo- 
tide (FAD), 10 #g/ml pepstatin, 10 #g/ml antipain, 10 #g/ml soy- 
bean trypsin inhibitor, 10 #M leupeptin, 10/~M chymostatin, and 
0.5 mM PMSF. Each homogenate was then supplemented with 
10%  glycerol. NOS  activity was  measured by monitoring the 
conversion  of I~-[2,3-3H]arginine (DuPont-NEN,  Boston,  MA) 
to r-[2,3-3H]citrulline (19). 50-#1 samples were run in duplicate 
in the presence  or absence of I  mM N~ 
(t-NMA). To initiate the reaction, an equal volume of 50 mM Tris, 
pH 7.6, containing the following components, was added: 2 mg/ml 
BSA, 5 mM EGTA (to block calcium-dependent constitutive NOS 
activity), 2 mM DTT, 20 #M FAD, 100 #M tetrahydrobiopterin, 
2 mM NADPH,  and 60 #M  t-arginine containing 0.9 #Ci  of 
r-[2,3-3H]-arginine.  After incubation  at  37~  for 40  rain,  the 
reaction was terminated by addition of 300 #1 cold stop buffer 
containing 10 mM EGTA, 100 mM Hepes,  pH 5.5, and 1 mM 
L-citrulline. The [3H]citrulline  was separated by chromatography 
on Dowex 50W X-8 cation exchange resin (Sigma Chemical Co.) 
and radioactivity quantified with a liquid scintillation  counter. 
Immunohistocheraistry.  Immunohistochemical staining ofiNOS 
was performed using 10 #m frozen sections of the allograft heart, 
isograft heart, and normal ACI rat heart (n  -- 3 for each group). 
Tissues were fixed with 1% paraformaldehyde,  pH 7.2, for 5 rain 
at room temperature, followed by 100% ethanol for 5 rain at 4~ 
Nonspecific binding was blocked with 3% normal goat serum in 
0.5 M Tris-HC1, pH 7.4, for 1 h at room temperature. All subse- 
quent incubations were carried out in this buffer. Tissue sections 
were incubated with 1:1,000 dilution of either preimmune rabbit 
sera or an anti-iNOS antisera generated in rabbits to a unique pep- 
tide sequence obtained from the COOH-terminal region of mu- 
rine iNOS (AVFSYGAKKGSALEEPKATRL) for 16 h at 4~  En- 
dogenous peroxidase activity was reduced with periodic acid (Zymed 
Laboratories,  Inc., S. San Francisco, CA) for 45 s at room tempera- 
ture, followed by sequential incubations with biotinylated anti-rabbit 
IgG and avidin-biotin-peroxidase complex (Vector Laboratories, Inc., 
Burlingame, CA) for 2 h each. The reaction product was visual- 
ized using 3,Y-diaminobenzidine intensified  with nickel chloride 
for 6 min. Tissue sections were counterstained with Mayer's hema- 
toxylin and mounted. 
Aminoguanidine  Administration.  Aminoguanidine-treated allo- 
grafts received continuous intravenous infusion of aminoguanidine 
hemisulfate  (Sigma  Chemical  Co.)  in  0.9%  NaC1  (600 
mg.kg-l.d -~) via a right external jugular vein cannula  connected 
to a subcutaneously implanted osmotic infusion pump (Alza Corp., 
Palo Alto, CA) from the time of transplantation until harvest  on 
postoperative day 8 (POD-8) for histologic and electron paramag- 
netic resonance spectroscopy (EPR) analysis or until complete re- 
jection occurred. Control allografts  received continuous IV infu- 
sion  of 0.9%  NaC1  from a similarly  implanted pump.  For the 
papillary muscle experiments,  aminoguanidine-treated  allografts re- 
ceived 100 mg/kg of aminoguanidine subcutaneously every 6 h 
beginning  at  the  time  of transplantation  (total  dose  of 400 
mg.kg-l.d -1)  until  harvest  on  POD-4.  Control  allograft  and 
isograft rats received 0.9% NaC1 subcutaneously in a similar fashion. 
Contractile Function of the Grafied Heart.  Isolated right ventric- 
ular papillary  muscle function was determined essentially  as de- 
scribed (20). Briefly, the native or the grafted heart was explanted 
into oxygenated modified Tryode's solution which had the following 
composition ([mM] 5.0 K +, 140.0 Na +, 0.5 Ca  2+, 28.0 HCO3-, 
1.2 PO4  2- ,  1.2 Mg  2+, 1.2 SO42-, and 5 glucose) and a right ven- 
tricular papillary muscle excised, mounted in a tissue perfusion bath 
attached to a calibrated  force transducer (model FT03; Grass In- 
struments, Quincy MA), and superfused  with the same solution 
equilibrated  with 95% 02/5% CO2 to a final pH of 7.4 at 31~ 
The muscles were field stimulated with platinum electrodes  (0.3 
Hz, 6-millisecond duration) at two times the pacing threshold. 
After an initial recovery period of 30 min, the muscles were loaded 
to the length of maximal activation and equilibrated for 90 min, 
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sion  developed  during  isometric contraction was  continuously 
recorded on an analog chart recorder (KS 3400; Gould Electronics, 
Cleveland,  OH). The maximal tension developed at each [Ca  z+] 
was normalized to the mean cross-sectional  area and reported as 
miUinewtons/mm  3. 
EPR.  EPK was performed on the allografted heart on POD-4 
(n =  4), POD-5 (n =  4), POD-8 (n  =  7); on the aUograft native 
heart on POD-8 (n =  4); on the aminoguanidine-treated allograft 
heart on POD-8 (n  =  7); and on the isografted heart on POD-8 
(n  =  4).  At the time of tissue harvest,  the left ventricular apex 
(,,~100 rag) was amputated, placed into a 4-mm quartz EPR tube 
(Wilmad Glass, Buena, NJ), flash frozen in liquid nitrogen, and 
stored at -70~  until analyzed (in triplicate) at 30~  on an X-band 
spectrometer (model ER200; Bruker, BiUerica, MA) equipped with 
an EPK cryostat (4.2-300  K; Oxford Sdentific, Concord, MA). 
Signal averaging and data processing were implemented by an ad- 
ditional 12-bit analog/digital converter and a Scientific EPK soft- 
ware package (Scientific Software Services, Bloomington, IL). Ex- 
perimental  settings  were:  microwave  frequency,  9.47  GHz; 
modulation frequency, 100 KHz; modulation amplitude, 5G; re- 
ceiver gain, 2.5  x  104;  and microwave power, 1.3 mW. The stable 
radical,  1,1-diphenyl-2-pierylhydrazyl  was used as a fidd marker 
(g  =  2.0036). 
Histology.  The grafted heart was rapidly excised, fixed in 10% 
neutral buffered formaldehyde,  embedded in paratfin,  cross-sec- 
tioned, stained with hematoxylin and eosin, and then graded for 
acute rejection using a modification of the BiUingham criteria (21). 
In a blinded fashion, four separate sections from each specimen were 
graded for both interstitial infiltrate and myocyte necrosis: 0  = 
no infiltrate or necrosis; 1 =  mild, scattered mononuclear infiltrate 
or rare necrosis; 2  =  moderate infiltrate or patchy necrosis; 3  = 
moderately severe infiltrate or necrosis;  4  =  severe infiltrate or 
necrosis;  and 5  =  complete rejection. 
Statistical Analysis.  Papillary muscle contractile function data 
and serum nitrite/nitrate measurements were analyzed by analysis 
of variance (ANOVA) with the Tukey HSD posthoc test for mul- 
tiple comparisons; histologic grading scores were compared by Stu- 
dent's unpaired t-test;  and graft survival data were compared  by 
Kaphn-Meier analysis  with the Mantel-Haenszel log rank test using 
SYSTAT (SYSTAT Inc., Evanston, IL). Data are expressed as mean 
_+  SEM unless  otherwise indicated,  with a p <0.05  considered 
statistically  significant. 
Results  and  Discussion 
The time course of NO production during cardiac allograft 
rejection was determined by measuring the systemic serum 
nitrite/nitrate levels  at  serial time points  after transplanta- 
tion (Fig.  1).  Nitrite  and nitrate are  stable endproducts  of 
NO metabolism and thus serve as indirect markers for the 
presence of NO  (2).  In this rat model, isograft  serum  ni- 
trite/nitrate levels did not vary from normal control values 
(15  _+  1 #M;  n  =  6) throughout the postoperative course. 
AUograft serum nitrite/nitrate levels were first elevated above 
isograft and normal control values on POD-4, coinciding with 
the first histologically detectable evidence of acute rejection. 
The fall in systemic serum nitrite/nitrate levels measured in 
the latter  stages of rejection likely reflect decreased release 
from the graft, possibly secondary to thrombosis and destruc- 
tion of the graft microvasculature, rather than reduced NO 
production (see discussion of EPR. results below). The two- 
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Serum nitrite/nitrate  levels  measured  at serial  time points  after  Figure  1. 
transplantation. Allograft  (ALLO) and isograft  (ISO) transplant  recipients 
were harvested  on the indicated  day and serum nitrite/nitrate levels mea- 
sured as described in Materials and Methods. Normal ACI control values 
were 15  _+  1 gM (n  =  6). Mean +  SEM; n =  4-7; significant  versus 
isograft at  *  z  iv <0.001 and ~ = iv <0.05. 
to fourfold elevation in allograft systemic serum nitrite/ni- 
trate levels  suggested that iNOS,  which is capable of sus- 
tained production of large quantities of NO, is induced during 
the rejection process. 
Using KT-PCR amplification, the specific expression of 
iNOS mKNA during acute transplant rejection was demon- 
strated in the aUograft heart on POD-5, but not in the isograft 
heart  (Fig.  2).  iNOS  activity in the allograft myocardium 
was demonstrated by the calcium-independent conversion of 
t-arginine to t-citruUine by crude homogenates of cardiac al- 
lografts harvested on POD-5.  t-citrulline production by the 
allografts was 40.4  +  9.8 pmol and was over 80% inhibited 
by  1  mM  r-NMA,  a  NOS  inhibitor  (7.1  _+  3.6  pmol). 
t-citruUine production could not be detected in isograft or 
normal hearts  (0  _+  0  pmol). 
Immunohistochemical staining of the allograft heart  on 
POD-6 localized the iNOS to the infiltrating inflammatory 
cells (Fig. 3 A). The cells that stained for iNOS were prin- 
cipaUy clustered at sites of ongoing myocyte necrosis (Fig. 
3 B). Although the inflammatory cell subtype cannot be pre- 
cisely identified from these experiments, the cell morphology 
is suggestive of macrophages or lymphoblasts, iNOS was not 
Figure 2.  KT-PCR  reaction  detection  of iNOS mRNA in the grafted 
heart on POD-5. iNOS mRNA is present in both allografts  tested, but 
not in the three isografts tested. 
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not appear to be induced in the aUograft endothelium, vas- 
cular smooth muscle, or myocytes. The RT-PCR,  enzyme 
activity, and immunohistochemical data demonstrate that bi- 
ologically active iNOS is expressed in the cells infiltrating 
the rejecting organ in a time frame consistent with a role 
in the rejection process. 
To determine the contribution of iNOS to the pathogen- 
esis of acute rejection, aminoguanidine, a selective iNOS in- 
hibitor, was systemically administered to allograft recipients. 
Graft  survival  was  significantly  prolonged  in  all  of  the 
aminoguanidine-treated animals as compared to identical grafts 
in control animals (Table 1). The grafted hearts survived an 
average of 15.0  _+  1.53 d in the aminoguanidine-treated al- 
lografts and 10.14 +  0.69 in the placebo-treated allograft con- 
trols. The prolongation of graft survival achieved with iNOS 
inhibition is like that obtained in a similar cardiac transplant 
model with low-dose cyclosporine A therapy or antibodies 
to tumor necrosis factor (22),  suggesting an important role 
for NO in mediating the in vivo immune response to allogeneic 
tissue. 
The effects of iNOS inhibition during in vivo rejection 
were further characterized by assessing the contractile func- 
tion  of the  grafted heart.  Papillary muscles isolated from 
aminoguanidine-treated allografts demonstrated significantly 
Figure 3.  Representative sections from  allograft  and isograft  hearts 
stained with iNOS antisera. (A) The cells staining for iNOS are intersti- 
tial inflammatory cells and thus appear to outline the myocytes (xS0). 
(B) When viewed at higher magnification, cells expressing iNOS seem 
to cluster at sites of active myocyte necrosis (x200). Similar staining was 
obtained in two additional allografts. There was no staining in the isograft 
heart  (C; n  =  3), the normal heart  (n  =  3), or with preimmune sera 
in any of the animals. 
improved contractile function compared with untreated al- 
lografts and did not differ significantly from isograft papil- 
lary muscles (Fig. 4). Aminoguanidine treatment normalized 
the serum nitrite/nitrate levels measured at the time of graft 
Table  1.  Inhibition  of iNOS Prolongs Cardiac Allografi 
Survival 
Treatment  Graft 
group  survival time 
Graft 
survival time 
(mean  _+ SD) 
d 
Control  9,  10,  10,  10,  10,  11,  11 
Aminoguanidine  [13], 14,  15,  15,  15,  15,  18 
10.14  +  0.69 
15.0  _+  1.53" 
Cardiac allograft recipients received treatment with either placebo or in- 
travenous aminoguanidine  from the time of transplantation until com- 
plete rejection. Graft survival was defined as the day after transplantation 
that palpable contractile  activity ceased. 
* Significant at p  <0.001;  [ ],  animal died with functioning graft  and 
most likely reflects the 5% pedoperative mortality rate with this model 
rather than the aminoguanidine treatment,  as we have not observed mor- 
tality with aminoguanidine in normal rats. 
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The contractile function of the grafted heart. Right ventric- 
ular papillary muscles were harvested on POD-4 from aminoguanidine- 
treated allograft (ALLD  + AG), untreated allograft (ALLO),  isograft 
(ISO), and normal Lewis (CON) hearts. Papillary muscle function was 
determined in response to a calcium challenge as described in Materials 
and Methods. ALLO-AG rats received 100 mg/kg of aminoguanidine sub- 
cutaneously every 6 h beginning at the time of transplantation.  ALLO 
and ISO rats received  0.9% NaC1 subcutaneously in a similar fashion. Mean 
+- SEM; n =  6; significant at p <0.005 versus isograft (*) and untreated 
allograft (t), respectively. 
harvest (19  _+  I vs 36  _+  7/~M, p <0.05; n  =  6). Graft dys- 
function during early cardiac rejection is thus mediated to 
a substantial degree by NO, and is therefore similar to cytokine- 
induced cardiac dysfunction, which is at least partially medi- 
ated by NO  (20,  23). 
EPR was used to examine the potential biochemical roles 
for NO in the pathogenesis of acute rejection. EPlL analysis 
of the allograft myocardium demonstrated a spedfic NO signal 
(24) that was variably and weakly present on POD-4,  uni- 
formly present and of moderate intensity on POD-5, and that 
had reached maximal intensity by POD-8 (Fig. 5). Isograft 
heart and allograft native hearts did not demonstrate a signal 
for NO (Fig. 5). The strong EPR signal on POD-8 suggests 
that there is ongoing NO production in the latter stages of 
rejection. Thus, the fall in systemic serum nitrite/nitrate levels 
measured on POD-8  and -10 may reflect decreased release 
from the graft secondary to the immune-mediated destruc- 
tion of the graft microvasculature, rather than reduced NO 
production. The EPR spectrum consists of a nitrogen hy- 
perfine [(14N); I  =  1] with splitting of 17.5 gauss centered 
at g  =  2.011  and an axial feature at g  =  2.040, indicating 
the formation of nitrosylferromyoglobin and/or nitrosylfer- 
rohemoglobin and of nonheme iron-dinitrosyl complexes, 
respectively (1, 24-26). Nitrosylferromyogtobin and nitrosyl- 
ferrohemoglobin are most likely formed because myoglobin 
and hemoglobin serve as biological sinks by spin trapping 
NO.  The appearance of the nonheme iron-dinitrosyl com- 
plex signal in the allograft myocardium is consistent with 
NO-mediated cytostasis/cytotoxicity through the nitrosyla- 
tion and inhibition of iron containing proteins such as mito- 
chondrial electron transport chain complexes I and II, mito- 
chondrial aconitase, and ribonucleotide reductase (5, 6, 25, 26). 
Aminoguanidine treatment uniformly eliminated the EPR 
signals for nitrosylferromyoglobin, nitrosylferrohemoglobin, 
and for the nonheme iron-dinitrosyl complexes in the allografts 
g=2.040 g=?.011 
I  19=2.004 
A 
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Figure 5.  Representative EPR spectra of allograft and isograft hearts. 
The grafted heart was harvested from untreated allografts on POD-5 (,4) 
and POD-8 (/3); and on POD-8 from aminoguanidine-treated  allografts 
(C) and untreated isografts (D). EPR was performed as described  in Materials 
and Methods.  n  =  4-7 for each group. 
(Fig. 5 C and Table 2). Eliminating the NO signal revealed 
a residual EPR signal (g  =  2.004) that is different from the 
isograft  signal  (Fig.  5  D)  and  that  is  not  an  artifact  of 
aminoguanidine treatment in that aminoguanidine-treated 
isografts  demonstrate  the  same  EPR  signal  as  untreated 
isografts (our unpublished observations), The residual signal 
seen in aminoguanidine-treated aUografts can be assigned to 
a semiquinone and/or a superoxide-free radical (27). Genera- 
tion of these free radicals has not been previously demon- 
strated during organ rejection. In unmodified rejection, su- 
peroxide could combine with NO to form peroxynitrite and 
subsequently decompose to hydroxyl radical and nitrogen di- 
oxide, which are much more toxic than NO itself (28). These 
breakdown products may be the actual effector molecules, 
and inhibition of iNOS could prevent their formation. 
To determine the effect of iNOS inhibition at the tissue 
level, histologic analysis of the grafted heart was performed. 
Aminoguanidine treatment from the time of transplantation 
until harvest of the grafted heart on POD-8 normalized the 
serum nitrite/nitrate levels and significantly improved the histo- 
logic stage of rejection (Fig. 6 and Table 2). Control allografts 
demonstrated a dense interstitial inflammatory cell infiltrate 
and severe myocyte necrosis. Aminoguanidine-treated aUografts 
were vigorously contracting at the time of harvest and demon- 
strated a significant reduction in myocardial necrosis. Perhaps 
67  Worrall et al. Table  2.  The Effect  of iNOS  Inhibition on NO Production and Histologic Rejection Grade 
Treatment  Myocardial necrosis  Interstitial  infiltrate 
group  EPR signal  Serum nitrite  (0-5)  (0-5) 
Control  Present 
(n  =  7) 
Aminoguanidine  Absent 
(.  =  7) 
30  _+  3  3.33  _+  0.52  3.50  _+  0.63 
11  _+  4*  1.64  _+ 0.24~  1.43  _+  0.35* 
Cardiac allograft recipients were treated with aminoguanidine or placebo from the time of transplantation until harvest on POD-8. The effect of 
iNOS inhibition on NO production and histologic rejection score were determined. 
* Mean _+ SD; significant versus control at p <0.001. 
* Mean _+ SD; significant versus control at/~ <0.0005. 
even more striking is the decreased inflammatory cell infiltrate, 
suggesting  a potential  role for NO  in  the  recruitment  of 
inflammatory  cells  to  the  site  of rejection. 
These findings demonstrate that NO generated by the in- 
duction of iNOS in the inflammatory cell infiltrate modu- 
lates the in vivo immune response to allogeneic tissue,  iNOS 
inhibition prevented the increased NO production in the trans- 
planted organ and significantly attenuated the pathogenesis 
of acute rejection,  as demonstrated by prolonged graft sur- 
vival, improved graft contractile function,  and a significant 
reduction in the histologic severity of rejection. NO may play 
both regulatory and effector roles during in vivo rejection; 
our data suggest that the net role of NO is to promote organ 
rejection. The potential immunoregulatory roles of NO have 
been demonstrated by discordant reports showing: (a) NOS 
inhibitor-mediated promotion of alloantigen- (12) and mito- 
gen-induced  (13)  T=lymphocyte  proliferation;  (b)  NOS 
inhibitor=mediated  suppression  of in  vitro  T-lymphocyte 
proliferation  (14);  and (c) NOS inhibitor-mediated  promo- 
tion of the in vitro proliferation and cytotoxicity of sponge 
matrix  allograft infiltrating  cells  (15).  These reports repre- 
sent in vitro experiments and thus may not reflect the hetero- 
geneous environment  of the in vivo rejection process. The 
in vitro immunosuppressive action of NO may be explained 
by the observation that the cytostatic and cytotoxic proper- 
ties of NO extend to the cells that produce it (29, 30), and 
thus may also extend to the other ceils present  in culture, 
such as lymphocytes. 
The  significant  reduction  in cellular infiltrate  seen  with 
iNOS inhibition suggests a potential role for NO in the migra- 
tion of inflammatory ceUs into the rejecting organ.  This is 
supported by the observation that  aminoguanidine  reduces 
the inflammatory cell infiltrate in endotoxin-induced uveitis 
(10) and in experimental autoimmune encephalomyelitis (11), 
and by the observation that NO mediates endothelial barrier 
dysfunction at the site of rejection (Worrall,  N.  K.,  K.  C. 
Chang,  G. M. Suau, R. G. Tilton,  T. P. Misko, J. R. Wil- 
liamson, and T. B. Ferguson, Jr., manuscript in preparation). 
Figure 6.  Representative  photomicrographs of  the subendocardial  region of phcebo  and aminoguanidine-treated  allografts  hearts harvested on POD-8. 
(A) Phcebo-treated allograft demonstrating the severe myocyte  necrosis and the dense mononuclear infiltrate characteristic of late rejection. (B) 
Aminoguanidine-treated allograft demonstrating the significant reduction in necrosis and infiltrate with iNOS inhibition, x50. 
68  Nitric  Oxide Modulates In Vivo Allograft Rejection The localization ofiNOS to the infiltrating cells and the EPR 
signal for the iron-dinitrosyl complexes are consistent with 
a cytostatic/cytotoxic effector function of NO,  possibly in 
combination with the generation of oxygen-free radicals. Elu- 
cidation of the molecular signals  regulating the induction 
and expression  of iNOS in this model may give further in- 
sight into the pathogenesis of acute rejection. Inhibition of 
iNOS may provide a novel therapeutic modality  in the manage- 
ment of acute transplant rejection and of other immune- 
mediated processes. 
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